The Science

Mercaptor makes drugs that respond dynamically to brain damage and disease. Based on established therapeutics re-engineered to include our proprietary chemistry, these drugs – called Captons™ – have capabilities without historical precedent. Captons undergo structural modification upon encountering distressed tissue, in direct proportion to the level of pathology present. Modification activates the drug, generating known therapeutics at the site of damage, localizing treatment, leaving healthy brain tissue untouched.

Mercaptor has a number of Capton molecules under development. Initial studies are intended to test these molecules in seizures and traumatic brain injury (TBI). Additional studies in stroke and amyotrophic lateral sclerosis are planned. The list of indications anticipated to benefit from Capton technology includes:

Three phases of the Alzheimer disease. 1. Healthy neuron. 2. Neuron with aggregation of amyloid (yellow). 3. Dead neuron being digested by microglia cells (red).
  • Traumatic Brain Injury (TBI)
  • Alzheimer’s disease
  • Parkinson’s disease
  • Amyotrophic lateral sclerosis (ALS)
  • Chronic traumatic encephalopathy (CTE)
  • Seizure
  • Stroke
  • Alcohol withdrawal
  • Chemo brain
  • Epilepsy in animal companions

Most drugs cannot differentiate between healthy and diseased tissue. Captons can, acting specifically in areas burdened by severe oxidative stress within the brain. This type of stress is the hallmark of excitotoxicity and related pathologies, neuroinflammation, and neurodegeneration. Captons would be the first drugs on the market to address excitotoxicity directly, holding the promise of meaningful relief for patients who currently can expect little.

Capton performance derives from direct engagement with reactive-oxygen species (ROS) and redox-active metal ions, fundamental drivers of brain damage and disease. Coordinate oxidation of the Capton results, a structural alteration that releases therapeutic potencies otherwise silenced. As with all drugs, additional chemical characteristics define the therapeutic target and physiological effects of each activated drug. Captons under development exhibit mechanisms-of-action with demonstrated potential in the treatment a variety of CNS indications.